AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

Loading news article.

AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival | WAPE

AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

Article summary

Related companies

Comments —